The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Ipsen's 2013 oncology sales performance.
Ipsen has announced that its phase 3 study of Onivyde (irinotecan liposome injection), as part of an investigational treatment regimen called Nalirifox, met its primary endpoint of improvement in overall survival ... Ipsen’s executive vice president
Ipsen has announced it will acquire rare disease specialist Albireo for $952m in a deal that is set to strengthen the French biopharma’s liver disease pipeline. ... Through the acquisition, Ipsen will gain access to Bylvay (odevixibat), a non-systemic
Ipsen is a global leader in PCa treatment with a strong reputation for physician and patient support. ... Ipsen aims to bring honesty, authenticity, and individualisation to the heart of conversations and treatment decisions relating to PCa.
Putting the ‘Real Man’ with Prostate Cancer at the Heart of Treatment Decisions and Conversations - by Ipsen with support from Uptake Strategies.
Putting the ‘Real Man’ with Prostate Cancer at the Heart of Treatment Decisions and Conversations - by Ipsen with support from Uptake Strategies.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...